

Drug Coverage Decision for B.C. PharmaCare

About PharmaCare

B.C. PharmaCare is a government-funded drug plan. It helps British Columbians with the cost of eligible prescription drugs and specific medical supplies.

Details of Drug Reviewed

Drug	Enoxaparin biosimilar		
Brand Name	Elonox® and Elonox® HP		
Dosage Forms	Elonox®	Pre-filled syringe (PFS)	30 mg/0.3 mL 40 mg/0.4 mL 60 mg/0.6 mL 80 mg/0.8 mL 100 mg/mL
	Elonox® HP	PFS	120 mg/0.8 mL 150 mg/mL
Manufacturer	Fresenius Kabi Canada Ltd.		
Submission Type	Biosimilars		
Use Reviewed	The treatment and prophylaxis of venous thromboembolism (VTE).		
Canadian Agency for Drugs and Technologies in Health (CADTH) Reimbursement Reviews (CRR)	No, the CRR did not review.		
Provincial Review	In June 2019, CADTH provided confirmation that a CRR submission for enoxaparin biosimilar for the same indications as the reference biologic, Lovenox® and Lovenox® HP is not required; as such, a full Drug Benefit Council (DBC) review is not required and the Ministry's drug coverage decision will be based on an internal review only.		

Drug Coverage Decision	Limited Coverage Benefit. Access the enoxaparin criteria from www.gov.bc.ca/pharmacarespecialauthority
Date	June 1, 2023.
Reasons	<ul style="list-style-type: none"> • Health Canada’s review concluded that the enoxaparin biosimilar was similar to and had no clinically meaningful differences from the biologic reference drug, with respect to efficacy, safety, and pharmacodynamics. • Results from a CADTH Rapid Response evaluating the efficacy of the enoxaparin biologic reference drug to biosimilar concluded that the enoxaparin biosimilar has comparable effectiveness to the biologic reference drug in the prevention or treatment of thrombosis and cardiovascular conditions. • Based on the submitted product price, the enoxaparin biosimilars cost significantly less than the reference biologic, Lovenox® and Lovenox® HP. • BC participated in the pan-Canadian Pharmaceutical Alliance (pCPA) negotiations that concluded agreement with the drug manufacturer for Elonox® and Elonox® HP.
Other Information	CADTH Rapid Response Biosimilar Enoxaparin for the Prevention or Treatment of Thrombosis and Cardiovascular Conditions web LINK .

The Drug Review Process in B.C.

A manufacturer submits a request to the Ministry of Health (Ministry).

An independent group called the [Drug Benefit Council \(DBC\)](#) gives advice to the Ministry. The DBC looks at:

- whether the drug is safe and effective
- advice from a national group called the [Canadian Agency for Drugs and Technologies in Health \(CADTH\) Reimbursement Reviews\(CRR\)](#)
- what the drug costs and whether it is a good value for the people of B.C.
- ethical considerations involved with covering or not covering the drug
- input from physicians, patients, caregivers, patient groups and drug submission sponsors

The Ministry makes PharmaCare coverage decisions by taking into account:

- the existing PharmaCare policies, programs and resources
- the evidence-informed advice of the DBC
- the drugs already covered by PharmaCare that are used to treat similar medical conditions
- the overall cost of covering the drug

Visit [The Drug Review Process in B.C. - Overview](#) and [Ministry of Health - PharmaCare](#) for more information.

This document is intended for information only.

It does not take the place of advice from a physician or other qualified health care provider.